HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / April 9, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery ...

Trial designed to evaluate safety, pharmacokinetics and pharmacodynamics, of Aspire's sublingual aspirin product Aspire anticipates releasing initial clinical data from trial at the end of the second ...

HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / April 9, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug ...

Phase 1 Study Design The objectives of this Phase 1 single dose clinical study are to evaluate the safety, pharmacokinetics and pharmacodynamics of Aspire's sublingual aspirin powder when ...

Aspire intends to request "fast track" approval on FDA application for its high-dose aspirin product HUMACAO ... 5 mg oral aspirin (approximately two 81 mg aspirin tablets).

However, combining studies using 50–60mg with studies using 75–81mg likely diluted the effect of the latter ... Chronic kidney disease (CKD) is one of few cautions to the use of aspirin in pregnancy, ...

A case involving chronic venous occlusion in a patient with a recently constructed AV loop graft sheds light on the ...

Forward-looking statements may generally be identified by the use of words such as 'estimate,' 'projects ... with control healthy subjects given 162.5 mg oral aspirin (approximately two 81 mg aspirin ...